A share price of Xilio Therapeutics Inc [XLO] is currently trading at $1.44, up 9.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XLO shares have gain 39.81% over the last week, with a monthly amount glided 84.62%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Xilio Therapeutics Inc [NASDAQ: XLO] stock has seen the most recent analyst activity on December 21, 2022, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $7. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 10, 2022, and set its price target to $36. On November 16, 2021, Raymond James initiated with a Outperform rating and assigned a price target of $31 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $32 on November 16, 2021. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on November 16, 2021.
Xilio Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.49 and $2.89. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Xilio Therapeutics Inc [NASDAQ: XLO] shares were valued at $1.44 at the most recent close of the market. An investor can expect a potential return of 386.11% based on the average XLO price forecast.
Analyzing the XLO fundamentals
Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -12.68%, Pretax Profit Margin comes in at -12.46%, and Net Profit Margin reading is -12.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -1.77 and Total Capital is -1.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3267 points at the first support level, and at 1.2133 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5467, and for the 2nd resistance point, it is at 1.6533.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xilio Therapeutics Inc [NASDAQ:XLO] is 2.02. As well, the Quick Ratio is 2.02, while the Cash Ratio is 1.94. Considering the valuation of this stock, the price to sales ratio is 27.88, the price to book ratio is 1.89.
Transactions by insiders
Recent insider trading involved GILEAD SCIENCES, INC., 10% Owner, that happened on Apr 02 ’24 when 0.49 million shares were purchased. 10% Owner, Atlas Venture Fund XI, L.P. completed a deal on Feb 08 ’24 to sell 733.0 shares. Meanwhile, 10% Owner Atlas Venture Fund XI, L.P. sold 267.0 shares on Feb 08 ’24.
